Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature
Immune checkpoint inhibitors have emerged as a novel treatment in a wide variety of malignancies; however, it is associated with a distinctive array of side effects known as immune-related adverse events. Hyperprogression is defined as an accelerated growth of disease burden in patients treated with...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-03-01
|
| Series: | Journal of Investigative Medicine High Impact Case Reports |
| Online Access: | https://doi.org/10.1177/2324709621992207 |
| _version_ | 1818624010017046528 |
|---|---|
| author | Balraj Singh MD Parminder Kaur MD Michael Maroules MD |
| author_facet | Balraj Singh MD Parminder Kaur MD Michael Maroules MD |
| author_sort | Balraj Singh MD |
| collection | DOAJ |
| description | Immune checkpoint inhibitors have emerged as a novel treatment in a wide variety of malignancies; however, it is associated with a distinctive array of side effects known as immune-related adverse events. Hyperprogression is defined as an accelerated growth of disease burden in patients treated with immunotherapy. Limited literature is available regarding hyperprogression in hepatocellular cancer. We report a case of a 36-year-old male with no past medical history who presented with nausea, vomiting, and abdominal pain and was diagnosed with unresectable hepatocellular cancer and thereby started on atezolizumab and bevacizumab. The patient got only 1 cycle of treatment and unfortunately had hyperprogression of disease. |
| first_indexed | 2024-12-16T18:50:09Z |
| format | Article |
| id | doaj.art-82c558833cf343518c44aa41b9d50c16 |
| institution | Directory Open Access Journal |
| issn | 2324-7096 |
| language | English |
| last_indexed | 2024-12-16T18:50:09Z |
| publishDate | 2021-03-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Investigative Medicine High Impact Case Reports |
| spelling | doaj.art-82c558833cf343518c44aa41b9d50c162022-12-21T22:20:43ZengSAGE PublishingJournal of Investigative Medicine High Impact Case Reports2324-70962021-03-01910.1177/2324709621992207Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of LiteratureBalraj Singh MD0Parminder Kaur MD1Michael Maroules MD2Saint Joseph’s University Medical Center, Paterson, NJ, USASaint Joseph’s University Medical Center, Paterson, NJ, USASaint Joseph’s University Medical Center, Paterson, NJ, USAImmune checkpoint inhibitors have emerged as a novel treatment in a wide variety of malignancies; however, it is associated with a distinctive array of side effects known as immune-related adverse events. Hyperprogression is defined as an accelerated growth of disease burden in patients treated with immunotherapy. Limited literature is available regarding hyperprogression in hepatocellular cancer. We report a case of a 36-year-old male with no past medical history who presented with nausea, vomiting, and abdominal pain and was diagnosed with unresectable hepatocellular cancer and thereby started on atezolizumab and bevacizumab. The patient got only 1 cycle of treatment and unfortunately had hyperprogression of disease.https://doi.org/10.1177/2324709621992207 |
| spellingShingle | Balraj Singh MD Parminder Kaur MD Michael Maroules MD Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature Journal of Investigative Medicine High Impact Case Reports |
| title | Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature |
| title_full | Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature |
| title_fullStr | Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature |
| title_full_unstemmed | Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature |
| title_short | Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature |
| title_sort | hyperprogression in a patient with hepatocellular cancer treated with atezolizumab and bevacizumab a case report and review of literature |
| url | https://doi.org/10.1177/2324709621992207 |
| work_keys_str_mv | AT balrajsinghmd hyperprogressioninapatientwithhepatocellularcancertreatedwithatezolizumabandbevacizumabacasereportandreviewofliterature AT parminderkaurmd hyperprogressioninapatientwithhepatocellularcancertreatedwithatezolizumabandbevacizumabacasereportandreviewofliterature AT michaelmaroulesmd hyperprogressioninapatientwithhepatocellularcancertreatedwithatezolizumabandbevacizumabacasereportandreviewofliterature |